Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Zinc Finger Protein Transcription Factor-Mediated Repression of Alpha-Synuclein Expression as a Therapeutic Approach for Parkinson’s Disease

Download PDF